MedTrace Logo

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

NCT00866944 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2011-11-11

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.

Conditions

Interventions

DRUG

Adecatumumab

Adecatumumab,6-9mg/kg, every 14 days, 24 cycles

DRUG

Adecatumumab and FOLFOX

FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles

DRUG

FOLFOX 4

FOLFOX 4, every 14 days, 12 cycles

Sponsors & Collaborators

  • Amgen Research (Munich) GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Neuhaus, Prof. Dr. · Charité Campus Virchow Klinikum, Berlin

  • Patrick Dufour, Pr. Dr. · Centre Paul Strauss, Strasbourg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-07-31
Completion
2011-11-30

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866944 on ClinicalTrials.gov